Drugs /

taladegib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
taladegib
NCI Definition [1]:
An orally bioavailable small molecule antagonist of the Hedgehog (Hh)-ligand cell surface receptor smoothened (Smo) with potential antineoplastic activity. Taladegib inhibits signaling that is mediated by the Hh pathway protein Smo, which may result in a suppression of the Hh signaling pathway and may lead to the inhibition of the proliferation of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.

Clinical Trials

View Clinical Trials for taladegib

Taladegib has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating taladegib, 1 is phase 1 (0 open).

APH1A Mutation, DLL4 Amplification, and DLL4 Mutation are the most frequent biomarker inclusion criteria for taladegib clinical trials.

Breast carcinoma and soft tissue sarcoma are the most common diseases being investigated in taladegib clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Taladegib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating taladegib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ly2940680, 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide, 1258861-20-9, ly-2940680, smo receptor-specific hh signaling inhibitor ly2940680, taladegib, benzamide, 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)-
Drug Categories [2]:
SMO inhibitors
Drug Target(s) [2]:
SMO
NCIT ID [1]:
C103826

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.